Stay up-to-date on ReadyCell’s latest news, projects and developments.
Adari Cell visits ReadyCell’s facilities in Barcelona
The U.S. company Adari Cell Science met with ReadyCell at the Parc Científic de Barcelona and shared their impressions of the past year.
Play with us in the Science Week!
ReadyCell wants to contribute to the knowledge of science through scientific divulgation and didactics. For this purpose, we have prepared some games with scientific concepts to better understand processes.
ReadyCell has been accepted into the ICEX Next Program
ReadyCell SL in the context of the ICEX Next Program, has been supported by ICEX and co-financed by the European FEDER fund. The purpose of this support is to contribute to the international development of the company and its environment.
Cancer drug development: what to know about ABC transporters
The presence of the superfamily members of the ATP binding cassette (ABC) transporters is well established as the main cause of multidrug resistance, since they efflux therapeutic compounds from cells and reduce the intracellular drug levels.
Stretchbio holds a meeting in Denmark to evaluate the first 12 months of the project
Readycell participated in the annual meeting of the StretchBio Project, which was held at the Danmarks Tekniske Universitet (DTU) in Copenhagen.
A new study uses CacoGoblet in a gut-liver-organ-on-a-chip
An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).
Caco-2 Permeability Assay Protocol
Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.
ReadyCell is attending the 4th Brain Barriers Summit in Boston
Our ReadyCell sales representative Carla Sapienza will travel next August 29th, 30th and 31st to Boston to attend the Brain Barriers Summit, an event that aims to join industry experts through a discursive forum and evaluate how neuropharmaceuticals can be targeted.
New hyperoxia drug study references CacoReady Kits
The publication, entitled Daily Intraperitoneal Administration of RGZ Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.
Hepatic drug elimination: The role of OATPs and MRP2 transporters
OATP1B1 and OATP1B3 are two influx transporters of the SLCO gene family that are primarily expressed in the sinusoidal membrane of hepatocytes.